{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:35:39Z","timestamp":1777988139367,"version":"3.51.4"},"reference-count":23,"publisher":"Sociedade Brasileira de Cardiologia","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Bras. Cardiol."],"abstract":"<jats:p>Resumo  Fundamento: As evid\u00eancias sobre a efic\u00e1cia dos inibidores do cotransportador de s\u00f3dio-glicose 2 (iSGLT2) na insufici\u00eancia card\u00edaca (IC) associada \u00e0 amiloidose permanecem limitadas.  Objetivo: Avaliar o impacto dos iSGLT2 em pacientes com amiloidose por transtirretina amiloide (ATTR) ou por cadeias leves amiloides (AL) e IC.  M\u00e9todos: Utilizando dados globais de prontu\u00e1rios eletr\u00f4nicos, identificamos pacientes com idade \u2265 18 anos com amiloidose por ATTR ou AL e IC. Ap\u00f3s o pareamento, os desfechos foram comparados entre pacientes tratados com iSGLT2 e controles pareados, incluindo 2.036 pacientes com amiloidose por ATTR e 692 pacientes com amiloidose por AL. Os desfechos inclu\u00edram mortalidade por todas as causas em 12 meses, hospitaliza\u00e7\u00e3o e desfechos renais. A signific\u00e2ncia estat\u00edstica foi definida como p bilateral &lt; 0,05.  Resultados: Entre os pacientes com amiloidose por ATTR, ocorreram 96 (9,43%) \u00f3bitos no grupo iSGLT2, em compara\u00e7\u00e3o com 196 (19,2%) no grupo controle (hazard ratio [HR], 0,52; intervalo de confian\u00e7a 95% [IC 95%], 0,41-0,66). Hospitaliza\u00e7\u00f5es ocorreram em 387 (38,0%) pacientes em uso de iSGLT2 e em 505 (49,6%) controles (HR, 0,74; IC 95%, 0,65-0,84). Desfechos renais foram observados em 204 (20,0%) pacientes no grupo iSGLT2 e em 298 (28,5%) no grupo controle (HR, 0,72; IC 95%, 0,60-0,86). Entre os pacientes com amiloidose por AL, ocorreram 39 (11,2%) \u00f3bitos no grupo iSGLT2 e 80 (23,1%) no grupo controle (HR, 0,51; IC 95%, 0,34-0,74). Hospitaliza\u00e7\u00f5es ocorreram em 161 (46,5%) pacientes tratados com iSGLT2 e em 204 (58,96%) controles (HR, 0,71; IC 95%, 0,58-0,88). Desfechos renais ocorreram em 86 (24,8%) pacientes no grupo iSGLT2 e em 137 (39,6%) no grupo controle (HR, 0,60; IC 95%, 0,46-0,78).  Conclus\u00e3o: Em pacientes com IC decorrente de amiloidose por ATTR ou AL, o uso de iSGLT2 esteve associado a menor mortalidade por todas as causas, menor taxa de hospitaliza\u00e7\u00e3o e menor ocorr\u00eancia de desfechos renais.<\/jats:p>","DOI":"10.36660\/abc.20250439","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:07:13Z","timestamp":1772719633000},"source":"Crossref","is-referenced-by-count":0,"title":["Inibidores do Cotransportador de S\u00f3dio-Glicose 2 em Pacientes com Insufici\u00eancia Card\u00edaca e Amiloidose por Transtirretina ou de Cadeias Leves: An\u00e1lise do Mundo Real"],"prefix":"10.36660","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-2986","authenticated-orcid":false,"given":"Rafael Amorim Belo","family":"Nunes","sequence":"first","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-190X","authenticated-orcid":false,"given":"Leandro Menezes Alves da","family":"Costa","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-3633","authenticated-orcid":false,"given":"Thiago Luis","family":"Scudeler","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Precil Diego Miranda Menezes","family":"Neves","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Augusto Hamamoto","family":"Sato","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Avezum","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","published-online":{"date-parts":[[2026,1]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic Amyloidosis from A (AA) to T (ATTR): A Review","volume":"289","author":"Muchtar E","year":"2021","journal-title":"J Intern Med"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure","volume":"9","author":"Tahir UA","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan M","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis","volume":"140","author":"Lane T","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"ref6","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2020008737","article-title":"How I Treat AL Amyloidosis","volume":"139","author":"Palladini G","year":"2022","journal-title":"Blood"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac Amyloidosis Treatment","volume":"18","author":"Stern LK","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker SD","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon SD","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"ref11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-Glucose Co-Transporter 2 Inhibitor Therapy: Mechanisms of Action in Heart Failure","volume":"107","author":"Joshi SS","year":"2021","journal-title":"Heart"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1115413","DOI":"10.3389\/fmed.2023.1115413","article-title":"Possible Renoprotective Mechanisms of SGLT2 Inhibitors","volume":"10","author":"Nishiyama A","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ehf2.14567","article-title":"Dapagliflozin Treatment and Cardiovascular Outcome in RBP4\/TTRVal30Met (Transthyretin Cardiac Amyloidosis) Mice","volume":"11","author":"Li Z","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 Inhibitor Therapy for Transthyretin Amyloid Cardiomyopathy: Early Tolerance and Clinical Response to Dapagliflozin","volume":"10","author":"Dobner S","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in Patients with Transthyretin Cardiac Amyloidosis, a Well-Tolerated Option for Heart Failure Treatment? Results from a Small, Real-World, Patients Series","volume":"17","author":"Zampieri M","year":"2022","journal-title":"Intern Emerg Med"},{"issue":"24","key":"ref16","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy","volume":"83","author":"Porcari A","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"101405","DOI":"10.1016\/j.jacadv.2024.101405","article-title":"Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy","volume":"3","author":"Jaiswal V","year":"2024","journal-title":"JACC Adv"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"103100","DOI":"10.1016\/j.cpcardiol.2025.103100","article-title":"Impact of Sodium- Glucose Co-Transporter 2 Inhibitors in Mortality and Decongestion in Cardiac Amyloidosis: A Systematic Review and Meta-Analysis","volume":"50","author":"Santo C","year":"2025","journal-title":"Curr Probl Cardiol"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14392","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Outcomes in Transthyretin Amyloid Cardiomyopathy: Systematic Review and Meta-Analysis","volume":"55","author":"Karakasis P","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner C","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of Dapagliflozin on Development and Progression of Kidney Disease in Patients with Type 2 Diabetes: An Analysis from the DECLARE-TIMI 58 Randomised Trial","volume":"7","author":"Mosenzon O","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3390\/biomedicines10102458","article-title":"SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice","volume":"10","author":"Skrabic R","year":"2022","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2022e12284","article-title":"Renal Amyloidosis: A New Time for a Complete Diagnosis","volume":"55","author":"Feitosa VA","year":"2022","journal-title":"Braz J Med Biol Res"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":["Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Transthyretin or Light Chain Amyloidosis: A Real-World Analysis"],"link":[{"URL":"https:\/\/abccardiol.org\/wp-content\/uploads\/articles_xml\/0066-782x-abc-123-1-e20250439\/0066-782x-abc-123-1-e20250439.x74770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:07:17Z","timestamp":1772719637000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/inibidores-do-cotransportador-de-sodio-glicose-2-em-pacientes-com-insuficiencia-cardiaca-e-amiloidose-por-transtirretina-ou-de-cadeias-leves-analise-do-mundo-real\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["S0066-782X2026000100606"],"URL":"https:\/\/doi.org\/10.36660\/abc.20250439","relation":{"is-translation-of":[{"id-type":"doi","id":"10.36660\/abc.20250439i","asserted-by":"subject"},{"id-type":"doi","id":"10.36660\/abc.20250439i","asserted-by":"object"}]},"ISSN":["1678-4170","0066-782X"],"issn-type":[{"value":"1678-4170","type":"electronic"},{"value":"0066-782X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e20250439"}}